Heterocyclic Compounds

Matches 351 - 400 out of 36,810	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/247670A1	NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS The present invention provides compounds of formula (I) CB (I) or pharmaceutically acceptable salts thereof, wherein R3 to R5, R4a, B and C are as described herein, compositions including the compounds, processes of manufacturing the com...
WO/2023/250335A1	1,4-DIPHENYL-1 H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1 H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER The present disclosure relates to compounds of Formula (I): The compounds disclosed herein are useful for modulating PD-1 activity, PD-L1 activity (programmed cell death protein 1), and/or the PD-1/PD-L1 interaction and may be used in th...
WO/2023/248255A1	BETA CARBOLINE ANALOGUES AS SELECTIVE AND BIASED KAPPA OPIOID RECEPTORS AGONISTS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS The present invention relates selective for Kappa opioid receptor (KOR) agonist compounds, their tautomeric forms, their pharmaceutically accepted salts, or prodrugs thereof, which are useful for the treatment or prevention of various di...
WO/2023/245329A1	MULTI-KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME Provided are compounds of Formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula I, a tautomer the...
WO/2023/248010A2	TARGETED MODULATORS OF JAK3 FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES JAK3 inhibitors are described that contain a combination of 2 or more of the following moieties: a cyano-containing Michael acceptor, a l,6-dihydroimidazo[4,5-d]pyrrolo[2,3- b]pyridin, and a targeting factor to increase myeloid cell upta...
WO/2023/247593A1	PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/247590A1	TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
WO/2023/247754A1	BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES The present invention relates to bifunctional molecules which contain a protein-of-interest binding moiety linked through a linker group to a cellular receptor binding moiety preferably a moiety which binds to the receptor sortilin encod...
WO/2023/250181A1	TRIAZOLE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
WO/2023/250064A1	TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of TYK2 and in the treatment of a variety of TYK2 mediated conditions or diseases.
WO/2023/250082A2	SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecule compounds having a 6,6-heterocyclic structure (e.g., compounds having a naphthyridine, pyrido-pyridazine, pyrido...
WO/2023/246490A1	MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME Provided are compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer...
WO/2023/250430A1	BICYCLIC AMINE CDK12 INHIBITORS The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same
WO/2023/246925A1	ESTER COMPOUNDS AND USE THEREOF Disclosed in the present invention are compounds or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers or isotope labeled compounds thereof. The compounds are as shown in formula (I)....
WO/2023/246777A1	K-RAS MUTANT PROTEIN INHIBITORS The invention relates to KRAS mutant protein inhibitors of formula (I) or formula (II), a composition containing the same and the use thereof.
WO/2023/245327A1	MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME Provided are compounds of Formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula I, a tautomer the...
WO/2023/246837A1	CLASS OF COMPOUNDS HAVING PYRIMIDO-SIX-MEMBERED RING STRUCTURE, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF The present invention relates to a class of compounds having a pyrimido-six-membered ring structure, pharmaceutical compositions comprising same, and use thereof. The compounds have a structure represented by formula (I) below. Experimen...
WO/2023/243686A1	DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF The present invention provides a compound that exhibits a PLD-inhibitory activity.　The present invention provides a compound having the following structural formula or the like, or a pharmaceutically acceptable salt thereof. (Each symb...
WO/2023/245137A1	SLOW SKELETAL TROPONIN ACTIVATORS Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also provided herein is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a stereoisomer or tautomer thereof, or...
WO/2023/241322A1	HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF Provided are heterocyclic derivatives as shown in Formula (I), pharmaceutical compositions comprising them, a process for their preparation, and their use as therapeutic agents.
WO/2023/244917A1	1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS This disclosure provides compounds of Formula (I) (e.g., Formula (I-1), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)), or Formula (I-b) (e.g., Formula (I-b-1) or (I-b-2))), or a pharmaceutically ac...
WO/2023/242537A1	GPR65 MODULATORS One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (Formula (I)) wherein: ring B is: a monocyclic aromatic group; or a monocyclic or bicyclic heteroaromatic group, ...
WO/2023/244587A1	METHODS OF MAKING TOLEBRUTINIB Disclosed herein are improved synthetic routes for making (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl) -1 H-imidazo[4,5-c ]pyridin-2(3H)-one (tolebrutinbib). Also disclosed herein are novel compounds used in the synthesis...
WO/2023/241608A1	CSF-1R INHIBITORS AND USES THEREOF The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.
WO/2023/241598A1	AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF IN PREPARATION OF ESTROGEN RECEPTOR DEGRADER The present invention provides an aromatic compound, a method for preparing same, and use thereof in the preparation of an estrogen receptor degrader, and belongs to the technical field of chemical medicines. The aromatic compound is a c...
WO/2023/241644A1	FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Disclosed in the present invention are a five-membered ring-fused six-membered compound, a preparation method therefor, and a pharmaceutical composition and the use thereof. Provided in the present invention is a compound as represented ...
WO/2023/245091A1	PYRIDAZINONE-DERIVED COMPOUNDS FOR THE MODULATION OF MYC AND FOR MEDICAL USES Compositions, systems, and methods are described herein for the modulation, and in particular the reduction or inhibition, of expression or activity of MYC in a cell, animal or human subject. Such compositions, systems, and methods are u...
WO/2023/244600A1	PRODRUGS OF PAN-KRAS INHIBITORS The present invention relates to prodrugs of specific compounds that inhibits multiple mutated forms of KRas, i.e., the pan-KRas inhibitors. In particular, the present invention relates to prodrugs of these pan-KRas compound, pharmaceuti...
WO/2023/244815A1	MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.
WO/2023/242631A1	ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME The present disclosure relates compounds for inhibiting ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), or a pharmaceutically acceptable salts thereof.
WO/2023/244672A1	2-(IMIDAZO[1, 2-A]1,8-NAPHTHYRIDIN-8-YL)-1,3,4-OXADIAZOLE DERIVATIVES AS ENHANCERS OF INNATE IMMUNE RESPONSE FOR THE TREATMENT OF VIRAL INFECTIONS The present invention relates to 2-(imidazo[l,2-a]l,8-naphthyridin-8- yl)-l,3,4-oxadiazole derivatives of formula (I) as enhancers of innate immune response for the treatment of viral infections
WO/2023/241618A1	AMINOPYRIMIDINE COMPOUNDS AND USE THEREOF Disclosed are a series of aminopyrimidine compounds and use thereof, and specifically disclosed are a compound represented by formula (XI), a stereoisomer thereof and a pharmaceutically acceptable salt thereof, and use thereof.
WO/2023/244806A1	COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI/SNF-related matrix-assoc...
WO/2023/241569A1	AZA-ADAMANTANE COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT The present invention relates to the technical field of organic electroluminescent materials, in particular to an aza-adamantane compound and an organic electroluminescent element. The structural formula of the aza-adamantane compound is...
WO/2023/241290A1	PHARMACEUTICAL COMPOUND BASED ON QUINOLIZIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to the technical field of anti-tumor and anti-nerve-injury drug synthesis. Disclosed are an anti-tumor and anti-nerve-injury pharmaceutical compound based on a quinolizidine derivative, a use and a preparati...
WO/2023/241627A1	CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF The disclosure provides for compounds and methods for modulating or inhibiting CDK8/19.
WO/2023/239227A1	NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT The present invention relates to a novel compound that regulates the function and differentiation of the cytoskeleton, which is involved in pulmonary fibrosis, and thus is useful in the preparation of drugs that can treat associated dise...
WO/2023/237732A1	RSV INHIBITING TRIAZOLO BEARING DERIVATIVES The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...
WO/2023/236814A1	COMPOUND AND USE THEREOF IN PREPARATION OF BCL-XL INHIBITOR Disclosed in the present invention is a compound and the use thereof in preparation of a BCL-XL inhibitor, belong to the field of pharmacy. The structure of the compound provided by the present invention is represented in formula I. The ...
WO/2023/237041A1	BICYCLIC SUBSTITUTED AROMATIC CARBOXYLIC ACID ESTER COMPOUND Disclosed in the present invention is a bicyclic substituted aromatic carboxylic acid ester compound. Specifically, disclosed are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
WO/2023/240038A1	TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)),...
WO/2023/238930A1	ANALOGUES OF AZABICYCLIC COMPOUNDS Provided are novel compounds which are analogues to be removed from APIs and formulations. Also provided are standard products of analogues to be used in controlling the qualities of medicines. Analogue 1: 3-ethyl-4-\{4-[4-(1-methyl-1H-p...
WO/2023/236982A1	PHENANTHRIDINE DERIVATIVE AND USE THEREOF The present invention relates to the technical field of organic electroluminescent materials, and in particular to a phenanthridine derivative and the use thereof. The phenanthridine derivative having a structural formula shown in formul...
WO/2023/236960A1	CARBOXAMIDE DERIVATIVE HAVING RSK INHIBITORY EFFECT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Provided in the present invention are a carboxamide derivative having an RSK inhibitory effect, a pharmaceutical composition comprising same, and the use thereof. Specifically, provided in the present invention are a carboxamide derivati...
WO/2023/239629A1	COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 This disclosure provides compounds and pharmaceutically acceptable salts thereof that are useful as modulators of targeted ubiquitination. The compounds disclosed herein bind to and degrade one or more cyclin dependent kinases 2 (CDK2).
WO/2023/240253A2	MODULATORS OF TNF-ALPHA ACTIVITY Provided herein are inhibitors of TNF-α, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-α inhibitory compounds for the treatment of diseases or disorders.
WO/2023/236199A1	CRYSTAL OF N-(BENZOYL)-PHENYLALANINE COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a crystal of an N-(benzoyl)-phenylalanine compound and a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. Specifically, the compound is as represented by formula ...
WO/2023/240189A1	TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2023/236426A1	AUTOMATIC CONTINUOUS FLOW SEMI-SYNTHESIS METHOD FOR VINCAMINE Disclosed in the present invention is an automatic continuous flow semi-synthesis method for vincamine, belonging to the technical field of vincamine preparation. The method is carried out in an automatic continuous flow semi-synthesis d...
WO/2023/240188A1	PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.

Matches 351 - 400 out of 36,810	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >